Previous 10 | Next 10 |
2024-01-25 11:45:37 ET Summary Exact Sciences reported a 17% increase in total revenue in Q4 2023, driven by the Screening and Precision Oncology segments. The company's innovative products, such as Cologuard and Oncotype DX, are reshaping cancer screening and treatment paradigms....
2024-01-22 08:00:00 ET Cathie Wood leads Ark Invest, an investment management firm that rose to prominence in the early days of the pandemic. Although the subsequent years were a bit harsher, Wood bounced back in 2023 -- along with much of the market. Ups and downs aside, Wood's exchange-tr...
2024-01-18 21:08:20 ET Summary ARK Invest's 13F portfolio value increased by 29% this quarter, reaching approximately $16.89 billion. The top three holdings in the portfolio are Coinbase Global, UiPath, and Tesla. ARK Invest made new stakes in ProShares Bitcoin Strategy ETF an...
2024-01-17 21:22:40 ET Summary Shares of Oxford Nanopore declined by 33% after slower than expected growth in the second half of 2023. Positive outlook on the company, but profitability not expected until 2026. Challenging market with slow adoption of new technology, but new p...
2024-01-08 02:31:01 ET More on Exact Sciences It's JPM time! Which medtechs are expected to issue updates this week? Benchmark upgrades Exact Sciences to buy, names it a "best idea" for 2024 For further details see: Exact Sciences reports preliminary Q4 results; ...
2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results PR Newswire Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion , submits next-generation Cologuard ® to FDA Announces Chief Financial Officer succession plan...
2024-01-02 11:29:08 ET More on Exact Sciences Exact Sciences Corporation 2023 Q3 - Results - Earnings Call Presentation Exact Sciences Looks Fairly Valued After Its Q3 Earnings Beat Exact Sciences Corporation (EXAS) Q3 2023 Earnings Call Transcript Guardant H...
2023-12-20 11:38:11 ET More on Guardant Health Guardant Health, Inc. (GH) Q3 2023 Earnings Call Transcript Guardant Health, Inc. 2023 Q3 - Results - Earnings Call Presentation Guardant Health: Peeling Back Economic Layers, Compressed Market Values Appear Justified ...
2023-12-17 05:43:00 ET Over the past decade, Ark Investment Management has established its niche on Wall Street by making sizable investments in disruptive and groundbreaking technologies. These include genomic research, robotics, artificial intelligence (AI), autonomous driving, and more. ...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...